AN2 Therapeutics Inc
NASDAQ:ANTX

Watchlist Manager
AN2 Therapeutics Inc Logo
AN2 Therapeutics Inc
NASDAQ:ANTX
Watchlist
Price: 1.18 USD -1.67% Market Closed
Market Cap: 32.3m USD

Relative Value

There is not enough data to reliably calculate the relative value of ANTX.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ANTX Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Multiples Across Competitors

ANTX Competitors Multiples
AN2 Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
AN2 Therapeutics Inc
NASDAQ:ANTX
32.3m USD 0 -1 0.8 0.8
US
Eli Lilly and Co
NYSE:LLY
984.9B USD 16.6 53.5 35.9 38.5
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 5.8 -157.8 0.4 1.9
US
Johnson & Johnson
NYSE:JNJ
525.1B USD 5.7 20.9 17.1 22.1
CH
Roche Holding AG
SIX:ROG
273.3B CHF 4.4 28.9 12.3 14.4
UK
AstraZeneca PLC
LSE:AZN
207.6B GBP 0 0.3 0 0
CH
Novartis AG
SIX:NOVN
218.5B CHF 5 19.3 15.4 19.9
US
Merck & Co Inc
NYSE:MRK
272.2B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
145.1B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average P/E: 21
Negative Multiple: -1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.5
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -157.8 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.9
29%
1
UK
AstraZeneca PLC
LSE:AZN
0.3
37%
0
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
15%
1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
AN2 Therapeutics Inc
NASDAQ:ANTX
Average EV/EBITDA: 41.4
0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.9
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
0.4
36%
0
US
Johnson & Johnson
NYSE:JNJ
17.1
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.3
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
0
10%
0
CH
Novartis AG
SIX:NOVN
15.4
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A